Cystic fibrosis transmembrane conductance regulator pre-messenger RNA (CFTR pre-mRNA)

The “mutant CFTR pre-mRNA” refers to the precursor mRNA molecule transcribed from the mutated CFTR gene before splicing occurs[7]. The CFTR pre-mRNA includes all exons and introns of the gene as initially transcribed in the nucleus. Numerous mutations in the CFTR gene cause cystic fibrosis, some of which disrupt normal splicing of this pre-mRNA, leading to exon skipping or aberrant mRNA molecules that fail to encode functional CFTR protein[7][10]. Studying these pre-mRNA intermediates is essential for understanding the diverse molecular effects of different CFTR mutations, many of which manifest by creating or abolishing splice sites or regulatory sequences required for correct processing[7]. While there are currently no drugs approved to directly target the CFTR pre-mRNA, novel gene editing (e.g., CRISPR/Cas9)[2] and splicing-correction approaches (such as antisense oligonucleotides) are in development targeting the RNA processing steps in an effort to fix functional errors at the level of pre-mRNA. Ultimately, CFTR pre-mRNA is a nucleic acid biomolecule, not a conventional drug target such as a protein receptor, enzyme, or transporter, so it is not canonically categorized as a therapeutic target itself[2][6][8][10]. **Notes on correctness:** - “Mutant CFTR pre-mRNA” is not a conventional drug target; it is an intermediate nucleic acid species. Clinically and in pharmacology, the objects of intervention are typically proteins (ion channel in this case), mature mRNA, or the gene itself. "Mutant CFTR pre-mRNA" may appear in research or in experimental therapeutics as a target of gene editing or splicing-correction therapy, but is not itself a canonical drug target. - For "molecular_classifications," this entity is a precursor messenger RNA rather than a protein, enzyme, receptor, transporter, or other established drug target class. - For "interacting_drugs" and "mechanism_of_action," there are no drugs with established clinical use or regulatory approval that directly interact with the pre-mRNA; therapies in preclinical or early clinical stages may attempt to modulate its processing, but this is not equivalent to having a defined drug-target relationship. **Summary:** CFTR pre-mRNA is a critical intermediate in the expression of CFTR protein. Mutations affecting its splicing play important roles in disease, but the molecule itself is not a canonical therapeutic target. Experimental therapies are in development to modulate its processing, offering a potential avenue for treatment of splicing or nonsense mutations in cystic fibrosis[2][4][7][10].

Other names

CFTR pre-mRNACFTR pre-messenger RNAmutant CFTR pre-mRNA

Not applicable (therapies may exploit CFTR pre-mRNA as a strategy for gene therapy, gene editing, or splicing correction, but there are no approved drugs acting directly at the pre-mRNA level)